Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Fra ...
The Company will provide further updates following communications with the FDA when additional information is available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback